Synthetically Lethal Nanoparticles for Treatment of Endometrial Cancer
- 詳細技術說明
- Dr. Salem and his colleagues at the University of Iowa have developedthe optimal nanoparticle formulation to enhance therapeutic efficacy in tumorswith mutant p53 through a comprehensive analysis of release profiles, cellularuptake, and cell viability. In a xenograft model of USC, this novel therapyresulted in marked inhibition of tumor progression and extended survival. Thisnovel formulation promoted synthetic lethality, specifically in USC withloss-of-function p53 mutation, enhancing the effectiveness of EC treatment withPTX.
- *Abstract
-
Endometrialcancer (EC) arises from the abnormal growth of cells in the lining of theuterus. Over the last five years, the incidence and mortality for EC have bothconsiderably increased, making EC one of the two cancers whose survival rate isworse today than in the 1970s. Uterine serous carcinoma (USC) is one of themost aggressive types of EC. Even though USC represents only 10% of all ECcases, it contributes to 39% of total EC deaths. USC is characterized by pooroutcomes and mutations in the tumor suppressor p53. The frontline treatment forUSC is paclitaxel (PTX), an anticancer drug; however, PTX does not havesynthetic lethality in tumors with mutant p53.
Dr. Salem and his colleagues at the University of Iowa have developedthe optimal nanoparticle formulation to enhance therapeutic efficacy in tumorswith mutant p53 through a comprehensive analysis of release profiles, cellularuptake, and cell viability. In a xenograft model of USC, this novel therapyresulted in marked inhibition of tumor progression and extended survival. Thisnovel formulation promoted synthetic lethality, specifically in USC withloss-of-function p53 mutation, enhancing the effectiveness of EC treatment withPTX.
Advantages
- Extremelyselective and lethal cancer treatment
- Inhibitionof tumor progression
- Extended survival
- Therapeuticopportunity for loss-of-function p53 mutation cancers
- Syntheticlethality achieved with PTX
- *Licensing
- MihaelaD. Bojin, PhD, CLP Sr.Licensing AssociateUniversityof Iowa Research Foundation2660UCCIowaCity, Iowa 52242Phone:(319)335-2723Email:mihaela-bojin@uiowa.edu
- 國家/地區
- 美國
